* was admitted to a hospital for covid-19 prior to randomization, or is hospitalized (inpatient) for any reason at randomization * has a known positive sars-cov-2 serologic test * has a positive sars-cov-2 antigen or molecular diagnostic test from a sample collected \>72 hours prior to randomization * is immunosuppressed, based on investigator's assessment * has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, mabs against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or within 5 half-lives of the investigational product (whichever is longer) prior to the screening visit * prior, current, or planned future use of any of the following treatments: covid-19 convalescent plasma, mabs against sars-cov-2, (eg, bamlanivimab), ivig (any indication), systemic corticosteroids (any indication), or covid-19 treatments (authorized, approved, or investigational) * prior use (prior to randomization), current use (at randomization), or planned use (within time period given per cdc guidance but no sooner than 22 days of study drug administration) of any authorized or approved vaccine for covid-19 * has known active infection with influenza or other non-sars-cov-2 respiratory pathogen, confirmed by a diagnostic test * has participated, is participating, or plans to participate in a clinical research study evaluating any authorized, approved, or investigational vaccine for covid-19 note: other protocol defined inclusion/exclusion criteria apply

* was admitted to a hospital for covid-19 prior to randomization, or is hospitalized (inpatient) for any reason at randomization * has a known positive sars-cov-2 serologic test * has a positive sars-cov-2 antigen or molecular diagnostic test from a sample collected \>72 hours prior to randomization * is immunosuppressed, based on investigator's assessment * has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, mabs against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or within 5 half-lives of the investigational product (whichever is longer) prior to the screening visit * prior, current, or planned future use of any of the following treatments: covid-19 convalescent plasma, mabs against sars-cov-2, (eg, bamlanivimab), ivig (any indication), systemic corticosteroids (any indication), or covid-19 treatments (authorized, approved, or investigational) * prior use (prior to randomization), current use (at randomization), or planned use (within time period given per cdc guidance but no sooner than 22 days of study drug administration) of any authorized or approved vaccine for covid-19 * has known active infection with influenza or other non-sars-cov-2 respiratory pathogen, confirmed by a diagnostic test * has participated, is participating, or plans to participate in a clinical research study evaluating any authorized, approved, or investigational vaccine for covid-19 note: other protocol defined inclusion/exclusion criteria apply

- was admitted to a hospital for covid-19 prior to randomization, or is hospitalized (inpatient) for any reason at randomization - has a known positive sars-cov-2 serologic test - has a positive sars-cov-2 antigen or molecular diagnostic test from a sample collected >72 hours prior to randomization - is immunosuppressed, based on investigator's assessment - has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, mabs against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or within 5 half-lives of the investigational product (whichever is longer) prior to the screening visit - prior, current, or planned future use of any of the following treatments: covid-19 convalescent plasma, mabs against sars-cov-2, (eg, bamlanivimab), ivig (any indication), systemic corticosteroids (any indication), or covid-19 treatments (authorized, approved, or investigational) - prior use (prior to randomization), current use (at randomization), or planned use (within time period given per cdc guidance but no sooner than 22 days of study drug administration) of any authorized or approved vaccine for covid-19 - has known active infection with influenza or other non-sars-cov-2 respiratory pathogen, confirmed by a diagnostic test - has participated, is participating, or plans to participate in a clinical research study evaluating any authorized, approved, or investigational vaccine for covid-19 note: other protocol defined inclusion/exclusion criteria apply

- was admitted to a hospital for covid-19 prior to randomization, or is hospitalized (inpatient) for any reason at randomization - has a known positive sars-cov-2 serologic test - has a positive sars-cov-2 antigen or molecular diagnostic test from a sample collected >72 hours prior to randomization - is immunosuppressed, based on investigator's assessment - has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, mabs against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or within 5 half-lives of the investigational product (whichever is longer) prior to the screening visit - prior, current, or planned future use of any of the following treatments: covid-19 convalescent plasma, mabs against sars-cov-2, (eg, bamlanivimab), ivig (any indication), systemic corticosteroids (any indication), or covid-19 treatments (authorized, approved, or investigational) - prior use (prior to randomization), current use (at randomization), or planned use (within time period given per cdc guidance but no sooner than 22 days of study drug administration) of any authorized or approved vaccine for covid-19 - has known active infection with influenza or other non-sars-cov-2 respiratory pathogen, confirmed by a diagnostic test - has participated, is participating, or plans to participate in a clinical research study evaluating any authorized, approved, or investigational vaccine for covid-19 note: other protocol defined inclusion/exclusion criteria apply

- was admitted to a hospital for covid-19 prior to randomization, or is hospitalized (inpatient) for any reason at randomization - has a known positive sars-cov-2 serologic test - has a positive sars-cov-2 antigen or molecular diagnostic test from a sample collected >72 hours prior to randomization - is immunosuppressed, based on investigator's assessment - has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, mabs against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or within 5 half-lives of the investigational product (whichever is longer) prior to the screening visit - prior, current, or planned future use of any of the following treatments: covid-19 convalescent plasma, mabs against sars-cov-2, ivig (any indication), systemic corticosteroids (any indication), or covid-19 treatments (authorized, approved, or investigational) - prior, current, or planned use during the study period of any authorized, approved, or investigational vaccine for covid-19 - has known active infection with influenza or other non-sars-cov-2 respiratory pathogen, confirmed by a diagnostic test note: other protocol defined inclusion/exclusion criteria apply

- was admitted to a hospital for covid-19 prior to randomization, or is hospitalized (inpatient) for any reason at randomization - has a known positive sars-cov-2 serologic test - has a positive sars-cov-2 antigen or molecular diagnostic test from a sample collected >72 hours prior to randomization - is immunosuppressed, based on investigator's assessment - has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, mabs against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or within 5 half-lives of the investigational product (whichever is longer) prior to the screening visit - prior, current, or planned future use of any of the following treatments: covid-19 convalescent plasma, mabs against sars-cov-2, ivig (any indication), systemic corticosteroids (any indication), or covid-19 treatments (authorized, approved, or investigational) - prior, current, or planned use during the study period of any authorized, approved, or investigational vaccine for covid-19 - has known active infection with influenza or other non-sars-cov-2 respiratory pathogen, confirmed by a diagnostic test note: other protocol defined inclusion/exclusion criteria apply